GT Medical Technologies Welcomes New GammaTile® Center of Excellence Program Designation
Recognizing exceptional leadership in patient education and clinical skill in the GammaTile procedure
TEMPE, Ariz., Oct. 13, 2026 /PRNewswire/ -- GT Medical Technologies, a company focused on improving the lives of patients with brain tumors, today announced Columbia University Irving Medical Center/New York-Presbyterian Hospital as the latest GammaTile® Center of Excellence Program designation.
The program recognizes leaders in patient care dedicated to advancing brain tumor treatment. Physicians and their institutions who receive this designation have demonstrated an exceptional level of expertise in the GammaTile procedure by meeting specific clinical criteria, annual case minimums, and ongoing education requirements.
The following physicians are now recognized with achievement:
- Brian J.A. Gill, MD, Neurological Surgeon
- Michael B. Sisti, MD, Neurological Surgeon
- Tony Wang, MD, Radiation Oncologist
"Columbia University Irving Medical Center/New York-Presbyterian Hospital is proud to offer innovative treatment options like GammaTile, which provide targeted radiation precisely where it is needed while minimizing exposure to healthy brain tissue," said neurological surgeon Dr. Brian J.A. Gill. "Receiving this designation is a meaningful acknowledgement of our team's dedication to advancing brain tumor care."
GammaTile is an innovative form of radiation therapy placed at the time of tumor removal surgery, delivering immediate, targeted radiation to the tumor site when cancer cells are at their lowest levels. Unlike conventional approaches, which often require a delay between surgery and radiation therapy to allow for wound healing, GammaTile eliminates this treatment gap. By delivering immediate, localized radiation directly at the tumor site, it is designed to maximize the treatment's effectiveness against remaining cancer cells and reduce the risk of regrowth.1
About GammaTile
GammaTile is FDA-cleared for newly diagnosed malignant (cancerous) and recurrent brain tumors and has been adopted by more than 150 leading centers across the United States, underscoring its growing acceptance in both academic and community healthcare settings.2 For more information, visit gammatile.com and follow @GammaTile on Facebook, Instagram, LinkedIn and X.
About GT Medical Technologies, Inc.
GT Medical Technologies was founded by a dedicated team of brain tumor specialists to address unmet needs in brain tumor treatment. The company is committed to improving the lives of patients with brain tumors through innovative solutions that elevate the standard-of-care.
Media Contact
Dawn Fallon
New Dawn Communications LLC
[email protected]
732-771-7808
References
- Garcia MA et al. J Neurooncol. 166:203-212 (2024).
- Data on file. GT Medical Technologies, Inc.
SOURCE GT Medical Technologies
Share this article